New treatment for liver disease caused by alcohol use
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease
This study is testing a new treatment for people with alcohol-related liver disease to see if an antibody that targets a specific protein can help reduce liver inflammation and improve liver health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10930848 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for alcohol-associated liver disease (ALD), which is a serious condition that can lead to liver failure. The study focuses on using an antibody that blocks a specific cytokine, IL-23, which is involved in the inflammatory process that damages the liver in individuals with a history of alcohol use disorder. By enrolling adult participants with moderate to severe alcohol use disorder and chronic liver disease, the research aims to evaluate the effectiveness of this treatment in reducing harmful inflammatory markers and improving liver health.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with a history of moderate to severe alcohol use disorder and chronic liver disease, but without severe liver dysfunction or cirrhosis.
Not a fit: Patients with severe hepatic dysfunction, cirrhosis, or those who do not have a history of alcohol use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from alcohol-associated liver disease, potentially improving their liver function and overall health.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting inflammatory pathways in liver disease, indicating potential for success in this novel treatment.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Loomba, Rohit — University of California, San Diego
- Study coordinator: Loomba, Rohit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.